Barclays lowered the firm’s price target on Tandem Diabetes (TNDM) to $51 from $53 and keeps an Overweight rating on the shares. The firm views the stock as “significantly oversold” post earnings and believes the pullback provides an attractive buying opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities
- Tandem Diabetes Care’s Earnings Call Highlights Growth and Challenges
- Tandem Diabetes Care Gains FDA Clearance for SteadiSet
- Tandem Diabetes price target lowered to $20 from $27 at TD Cowen
- Tandem Diabetes price target lowered to $24 from $59 at Canaccord